The burden of osteoarthritis (OA) is a heavy one, often leading to poor quality of life (QoL) due to functional limitations and loss of independence, poor sleep quality, fatigue, depressed mood, and increased healthcare expenditures. Additionally, comorbidities such as stroke, peptic ulcer, and metabolic syndrome must be considered. Therefore, proper assessment of a patient’s OA, the pain it causes, and the proper utilization of tools such as GAD-7 and PHQ-9 to assess anxiety and depression, are imperative for improving function and QoL.
Following a discussion on OA assessment strategies, this CME Outfitters Snack will focus on applying ACR/Arthritis Foundation guidelines and evaluating emerging data to meet unmet needs in the management of OA.
At the end of this CME/CE activity, participants should be able to integrate pain management tools for individual pain and function assessment, goal setting, and monitoring.
The following learning objectives pertain only to those requesting CNE or CPE credit: identify pain management tools for individual pain and function assessment, goal setting, and monitoring.
Supported by an educational grant from Pfizer Inc.
Physicians, PAs, nurse practitioners, and pharmacists.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Gibofsky reports that he is on the advisory committee for AbbVie Inc.; Aurinia Pharmaceuticals Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a consultant for AbbVie Inc.; Acquist Therapeutics, Inc.; Amgen Inc.; Eli Lilly and Company; Gilead Sciences, Inc.; Novartis; Pfizer Inc.; and Samumed. He is a stock shareholder (directly purchased) for AbbVie Inc.; Johnson & Johnson; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-102-H01-P.
Call us at 877.CME.PROS (877.263.7767).